Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 89-93, October 2007

Dual Therapy with ACE Inhibitors and Angiotensin II Receptor Blockers in Proteinuric IgA Nephropathy Patients

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China

Article Outline

Experimental evidence supports dual pharmacologic blockade of the renin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric renal disease. Nonetheless, exaggerated therapeutic benefits are frequently the rule rather than the exception in the experimental or trial setting. The difference between the clinical trial setting (efficacy) and actual practice (effectiveness) should be borne in mind before the recommendation of any new therapy as the standard of care. With this in mind, we examined the effectiveness and safety of dual therapy on a cohort of adults with proteinuric IgA nephropathy in a usual clinical setting. The primary end point was reduction in proteinuria, which has been shown to be a significant risk factor for end-stage renal disease. [Hong Kong J Nephrol 2007;9(2):89–93]

Key words:  angiotensin-converting enzyme (ACE) inhibitor , angiotensin II receptor blocker , IgA nephropathy , outcome , proteinuria

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Wolf G , Ritz E . Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications . Kidney Int . 2005;67:799–812
  2. MacKinnon M , Shurraw S , Akbari A , Knoll GA , Jaffey J , Clark HD . Combination therapy with an angiotensin receptor blocker and an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systemic review of the efficacy and safety data . Am J Kidney Dis . 2006;48:8–20
  3. Wilmer WA , Rovin BH , Hebert CJ , Rao SV , Kumor K , Hebert LA . Management of glomerular proteinuria: a commentary . J Am Soc Nephrol . 2003;14:3217–3232
  4. To KF , Choi PC , Szeto CC , Li PK , Tang NL , Leung CB , et al.   Outcome of IgA nephropathy in adults graded by chronic histological lesions . Am J Kidney Dis . 2000;35:392–400
  5. Lai FM , Szeto CC , Choi PC , Li PK , Chan AW , Tang NL , et al.   Characterization of early IgA nephropathy . Am J Kidney Dis . 2000;36:703–708
  6. Lai FM , Szeto CC , Choi PC , Li PK , Tang NL , Chow KM , et al.   Primary IgA nephropathy with low histologic grade and disease progression: is there a “point of no return”? . Am J Kidney Dis . 2002;39:401–406
  7. Fernandez-Juárez G , Barrio V , de Vinuesa SG , Goicoechea M , Praga M , Luño J . Dual blockade of the reninangiotensin system in the progression of renal disease: the need for more clinical trials . J Am Soc Nephrol . 2006;17:S250–S254
  8. Ma YC , Zuo L , Chen JH , Luo Q , Yu XQ , Li Y , et al.   Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease . J Am Soc Nephrol . 2006;17:2937–2944
  9. World Health Organization Collaborating Centre for Drug Statistics Methodology Anatomical Therapeutical Chemical (ATC) (1994) Classification Index Including Defined Daily Doses (DDDs) for Plain Substances. Oslo: WHO. Available at http://www.whocc.no/atcddd/ [Date accessed: March 25, 2007]
  10. Berger ED , Bader BD , Ebert C , Risler T , Erley CM . Reduction of proteinuria; combined effects of receptor blockade and low-dose angiotensin-converting enzyme inhibition . J Hypertens . 2002;20:739–743
  11. Kincaid-Smith P , Fairley K , Packham D . Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria . Nephrol Dial Transplant . 2002;17:597–601
  12. Rutkowski P , Tylicki L , Renke M , Korejwo G , Zdrojewski Z , Rutkowski B . Low-dose dual blockade of the reninangiotensin system in patients with primary glomerulonephritis . Am J Kidney Dis . 2004;43:260–268
  13. Hollengberg NK , Osei SY , Lansang MC , Price DA , Fisher ND . Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man . J Renin Angiotensin Aldosterone Syst . 2001;2:14–18
  14. Woo KT , Lau YK , Wong KS , Chiang GS . ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis . Kidney Int . 2000;58:2485–2491
  15. Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy . Clin Nephrol . 2003;60:318–326
  16. Park HC , Xu ZG , Choi S , Goo YS , Kang SW , Choi KH , et al.   Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy . Nephrol Dial Transplant . 2003;18:1115–1121
  17. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al  Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study . Am J Kidney Dis . 2006;47:751–760
  18. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy . Clin Nephrol . 2005;64:35–40
  19. Horita Y , Taura K , Taguchi T , Furusu A , Kohno S . Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy . Nephrology (Carlton) . 2006;11:426–466
  20. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy . Am J Kidney Dis . 1999;33:851–856
  21. Ponda MP , Hostetter TH . Aldosterone antagonism in chronic kidney disease . Clin J Am Soc Nephrol . 2006;1:668–677
  22. Nakao N , Yoshimura A , Morita H , Takada M , Rayano T , Ideura T . Combination treatment of angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial . Lancet . 2003;361:117–124
  23. Kanno Y , Takenaka T , Nakamura T , Suzuki H . Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors . Clin J Am Soc Nephrol . 2006;1:730–737
  24. Reddan DN , Owen WF . IgA nephropathy inhibitors of the renin angiotensin system: is reduction in proteinuria adequate proof of efficacy? . Am J Kidney Dis . 2001;38:182–185
  25. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio C, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis . Ann Intern Med . 2003;139:244–252
  26. Ruggenenti P . Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies . Semin Nephrol . 2004;24:158–167

PII: S1561-5413(08)60007-1

doi:10.1016/S1561-5413(08)60007-1

Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 89-93, October 2007

Article Tools